Franzoi, Maria Alice http://orcid.org/0000-0002-2470-6054
Lambertini, Matteo
Ceppi, Marcello
Bruzzone, Marco
de Azambuja, Evandro
Clinical trials referenced in this document:
Documents that mention this clinical trial
Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients
https://doi.org/10.1007/s10549-022-06525-3
Article History
Received: 25 October 2021
Accepted: 16 January 2022
First Online: 25 January 2022
Declarations
:
: M. Franzoi had none. M. Lambertini received consulting fees (e.g. advisory boards) and was a consultant or played an advisory role for Roche, Novartis, Lilly, and AstraZeneca. Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g. speakers’ bureaus); Speakers’ Bureau: Theramex, Takeda, Roche, Lilly, Novartis, Pfizer, and Sandoz. M. Ceppi had none. M. Bruzzone had none. E. de Azambuja received consulting fees (e.g. advisory boards) from Roche/Genentech, Novartis, Libbs, Pierre Fabre, and Lilly. Other author received honoraria from Roche/Genentech, SeaGen, and Zodiac Pharma, travel, accommodations, and expenses from Roche/Genentech, GlaxoSmithKline, and research funding from Roche/Genentech, AstraZeneca, Servier/Pfizer, and GlaxoSmithKline/Novartis.